What is Leerink Partnrs’ Estimate for TENX FY2029 Earnings?

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Equities researchers at Leerink Partnrs issued their FY2029 EPS estimates for Tenax Therapeutics in a research note issued on Tuesday, February 4th. Leerink Partnrs analyst D. Risinger forecasts that the specialty pharmaceutical company will earn $0.63 per share for the year. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share.

TENX has been the subject of a number of other research reports. Guggenheim started coverage on Tenax Therapeutics in a report on Monday, October 14th. They issued a “buy” rating and a $16.00 target price for the company. Leerink Partners assumed coverage on Tenax Therapeutics in a research report on Thursday, October 24th. They set an “outperform” rating and a $16.00 price objective on the stock. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Tenax Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $16.00.

Tenax Therapeutics Stock Performance

Shares of NASDAQ TENX opened at $5.99 on Wednesday. Tenax Therapeutics has a twelve month low of $2.77 and a twelve month high of $21.46. The company has a 50 day moving average of $6.05 and a 200 day moving average of $4.71.

Institutional Trading of Tenax Therapeutics

Several large investors have recently modified their holdings of TENX. Sphera Funds Management LTD. purchased a new stake in shares of Tenax Therapeutics in the 3rd quarter worth $101,000. Stonepine Capital Management LLC purchased a new stake in Tenax Therapeutics in the third quarter worth about $173,000. Finally, Vestal Point Capital LP bought a new position in shares of Tenax Therapeutics in the third quarter worth about $288,000. Institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.